BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 37245259)

  • 21. Hypocomplementemic urticarial vasculitis case with hemophagocytic lymphohistiocytosis following SARS-CoV-2 mRNA vaccination.
    Iwamura N; Eguchi K; Koga T; Tsutsumi K; Araki T; Aramaki T; Takatani A; Terada K; Ueki Y
    Immunol Med; 2023 Jun; 46(2):97-107. PubMed ID: 36950829
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The long term vaccine-induced anti-SARS-CoV-2 immune response is impaired in quantity and quality under TNFα blockade.
    Geisen UM; Rose R; Neumann F; Ciripoi M; Vullriede L; Reid HM; Berner DK; Bertoglio F; Hoff P; Hust M; Longardt AC; Lorentz T; Martini GR; Saggau C; Schirmer JH; Schubert M; Sümbül M; Tran F; Voß M; Zeuner R; Morrison PJ; Bacher P; Fickenscher H; Gerdes S; Peipp M; Schreiber S; Krumbholz A; Hoyer BF
    J Med Virol; 2022 Dec; 94(12):5780-5789. PubMed ID: 35945627
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of suspected and confirmed COVID-19 (SARS-CoV-2) vaccine hypersensitivity.
    Worm M; Alexiou A; Bauer A; Treudler R; Wurpts G; Dickel H; Buhl T; Müller S; Jung A; Brehler R; Fluhr J; Klimek L; Mülleneisen N; Pfützner W; Raap U; Roeseler S; Schuh S; Timmermann H; Heine G; Wedi B; Brockow K
    Allergy; 2022 Nov; 77(11):3426-3434. PubMed ID: 35722723
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Profiles After Allergic Reactions to Messenger RNA Coronavirus Disease 2019 Vaccine.
    Maron JS; Conroy M; Naranbai V; Samarakoon U; Motazedi T; Farmer JR; Freeman E; Banerji A; Bartsch YC; Gregory DJ; Poznansky MC; Alter G; Blumenthal KG
    J Infect Dis; 2022 Sep; 226(7):1231-1236. PubMed ID: 35325158
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acute urticaria alone after CoronaVac COVID-19 vaccination should not be a contraindication for revaccination.
    Triwatcharikorn J; Puaratana-Arunkon T; Punyaratabandhu P; Mongkolpathumrat P; Palapinyo S; Buranapraditkul S; Rerknimitr P; Klaewsongkram J
    Clin Exp Dermatol; 2022 Apr; 47(4):735-738. PubMed ID: 34609771
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
    Akova M; Unal S
    Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months.
    Hsu CM; Weiner DE; Manley HJ; Aweh GN; Ladik V; Frament J; Miskulin D; Argyropoulos C; Abreo K; Chin A; Gladish R; Salman L; Johnson D; Lacson EK
    Clin J Am Soc Nephrol; 2022 Mar; 17(3):403-413. PubMed ID: 35144972
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IL-13 determines specific IgE responses and SARS-CoV-2 immunity after mild COVID-19 and novel mRNA vaccination.
    Meltendorf S; Vogel K; Thurm C; Prätsch F; Reinhold A; Färber J; Heuft HG; Kaasch AJ; Hachenberg T; Weinzierl S; Schraven B; Reinhold D; Brunner-Weinzierl MC; Lingel H
    Eur J Immunol; 2022 Dec; 52(12):1972-1979. PubMed ID: 36271745
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors influencing the SARS-CoV-2 infection and vaccination induced immune response in rheumatoid arthritis.
    Nemeth D; Vago H; Tothfalusi L; Ulakcsai Z; Becker D; Szabo Z; Rojkovich B; Merkely B; Nagy G
    Front Immunol; 2022; 13():960001. PubMed ID: 36311767
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of association of anti-PEG antibodies with anaphylaxis after mRNA COVID-19 vaccination.
    Zhou ZH; Cortese MM; Fang JL; Wood R; Hummell DS; Risma KA; Norton AE; KuKuruga M; Kirshner S; Rabin RL; Agarabi C; Staat MA; Halasa N; Ware RE; Stahl A; McMahon M; Browning P; Maniatis P; Bolcen S; Edwards KM; Su JR; Dharmarajan S; Forshee R; Broder KR; Anderson S; Kozlowski S
    Vaccine; 2023 Jun; 41(28):4183-4189. PubMed ID: 37244808
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immune Responses to SARS-CoV-2 Vaccination in Young Patients with Anti-CD19 Chimeric Antigen Receptor T Cell-Induced B Cell Aplasia.
    Jarisch A; Wiercinska E; Huenecke S; Bremm M; Cappel C; Hauler J; Rettinger E; Soerensen J; Hellstern H; Klusmann JH; Ciesek S; Bonig H; Bader P
    Transplant Cell Ther; 2022 Jul; 28(7):366.e1-366.e7. PubMed ID: 35472554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding "Hybrid Immunity": Comparison and Predictors of Humoral Immune Responses to Severe Acute Respiratory Syndrome Coronavirus 2 Infection (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) Vaccines.
    Epsi NJ; Richard SA; Lindholm DA; Mende K; Ganesan A; Huprikar N; Lalani T; Fries AC; Maves RC; Colombo RE; Larson DT; Smith A; Chi SW; Maldonado CJ; Ewers EC; Jones MU; Berjohn CM; Libraty DH; Edwards MS; English C; Rozman JS; Mody RM; Colombo CJ; Samuels EC; Nwachukwu P; Tso MS; Scher AI; Byrne C; Rusiecki J; Simons MP; Tribble D; Broder CC; Agan BK; Burgess TH; Laing ED; Pollett SD;
    Clin Infect Dis; 2023 Feb; 76(3):e439-e449. PubMed ID: 35608504
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine.
    Kobashi Y; Shimazu Y; Kawamura T; Nishikawa Y; Omata F; Kaneko Y; Kodama T; Tsubokura M
    PLoS One; 2022; 17(6):e0269917. PubMed ID: 35687563
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines against SARS-CoV-2 are safe to administer in patients with antibodies to pegaspargase.
    Swanson HD; Hakim H; Hijano DR; Morton T; Cross S; Inaba H; Jeha S; Pui CH; Karol SE
    Cancer Med; 2023 Jan; 12(2):1552-1555. PubMed ID: 35837830
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term quantitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV (PWH).
    Tuan JJ; Zapata H; Barakat L; Andrews L; Behnegar A; Kim YW; Kayani J; Mutic S; Ryall L; Turcotte B; Critch-Gilfillan T; Zhao M; Salahuddin S; Gupta S; Sutton R; Friedland G; Emu B; Ogbuagu O
    BMC Infect Dis; 2022 Sep; 22(1):744. PubMed ID: 36131232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management: A GRADE assessment and international consensus approach.
    Greenhawt M; Dribin TE; Abrams EM; Shaker M; Chu DK; Golden DBK; Akin C; Anagnostou A; ALMuhizi F; Alqurashi W; Arkwright P; Baldwin JL; Banerji A; Bégin P; Ben-Shoshan M; Bernstein J; Bingemann TA; Bindslev-Jensen C; Blumenthal K; Byrne A; Cahill J; Cameron S; Campbell D; Campbell R; Cavender M; Chan ES; Chinthrajah S; Comberiati P; Eastman JJ; Ellis AK; Fleischer DM; Fox A; Frischmeyer-Guerrerio PA; Gagnon R; Garvey LH; Grayson MH; Isabwe GAC; Hartog N; Hendron D; Horner CC; Hourihane JO; Iglesia E; Kan M; Kaplan B; Katelaris CH; Kim H; Kelso JM; Khan DA; Lang D; Ledford D; Levin M; Lieberman JA; Loh R; Mack DP; Mazer B; Mody K; Mosnaim G; Munblit D; Mustafa SS; Nanda A; Nathan R; Oppenheimer J; Otani IM; Park M; Pawankar R; Perrett KP; Peter J; Phillips EJ; Picard M; Pitlick M; Ramsey A; Rasmussen TH; Rathkopf MM; Reddy H; Robertson K; Rodriguez Del Rio P; Sample S; Sheshadri A; Sheik J; Sindher SB; Spergel JM; Stone CA; Stukus D; Tang MLK; Tracy JM; Turner PJ; Vander Leek TK; Wallace DV; Wang J; Wasserman S; Weldon D; Wolfson AR; Worm M; Yacoub MR
    J Allergy Clin Immunol; 2023 Aug; 152(2):309-325. PubMed ID: 37295474
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.